US research roundup: Amgen, Carmax, Pfizer
AMGN•Analysts revised ratings and price targets for numerous US-listed companies on Wednesday. Amgen's target was raised by Leerink Partners to $464 from $395, while JP Morgan cut Carmax's to $65 from $70 and Morgan Stanley cut Pfizer's to $26 from $28.
1. Analyst actions
The roundup included multiple target-price changes for large and small US-listed companies. Amgen received several target increases, including Oppenheimer's move to $520 from $480 and TD Cowen's to $531 from $452; Pfizer had mixed changes, with RBC raising its target to $28 from $25 while Morgan Stanley cut its target to $26 from $28.
